10X Capital Management, LLC 4
4 · GALECTIN THERAPEUTICS INC · Filed Jun 14, 2018
Insider Transaction Report
Form 4
10X Fund, L.P.
10% Owner
Transactions
- Sale
Common Stock
2018-06-13$6.59/sh−60,000$395,400→ 2,949,786 total(indirect: See footnote) - Sale
Common Stock
2018-06-13$7.09/sh−60,000$425,400→ 2,889,786 total(indirect: See footnote) - Sale
Common Stock
2018-06-13$7.97/sh−28,140$224,276→ 2,801,646 total(indirect: See footnote) - Sale
Common Stock
2018-06-13$7.47/sh−60,000$448,200→ 2,829,786 total(indirect: See footnote)
Footnotes (2)
- [F1]Common shares should pursuant to a trading plan pursuant to Rule 10b5-1. Price represents the gross sales price less commissions and brokerage fees.
- [F2]10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.